Proceeds from the offering and any profits from related debt-financing transactions will go to J&J, but Kenvue will retain $1.17 billion in cash and cash equivalents. At that IPO price, the new company will be valued at around $41 billion.

But Kenvue said in the filing that “such indemnity may not be sufficient” to protect the new company against the full amount of liabilities. But Kenvue will assume only talc-related liabilities that arise outside the U.S. and Canada, according to its IPO filing from January. Kenvue noted that its global footprint is “well balanced geographically,” with roughly half of 2022 net sales coming from outside North America. Ten of Kenvue’s brands had approximately $400 million or more in sales last year. Kenvue posted $14.95 billion in sales for 2022 and a net income of $1.46 billion on a pro forma basis.

  1. This incredible responsibility means every decision and action we take is guided by integrity and quality.
  2. Our essential health brands have been raising standards of personal care across baby care, wound care, oral care and sanitary protection for generations.
  3. We’re working to improve the sustainability of our products, packaging and operations to build lasting positive change for people, communities and the one planet we call home.
  4. Meanwhile, Kenvue is chock full of household names familiar to investors and the larger public, such as Tylenol, Band-Aid, Listerine, Aveeno, Neutrogena, and J&J’s namesake baby powder and shampoo.
  5. Our work impacts consumers and colleagues, communities and generations, in daily rituals and in the moments that matter most.

This incredible responsibility means every decision and action we take is guided by integrity and quality. The company will have total debt of $8.9 billion, according to the filing. J&J will generally be able to control matters that shareholders vote on, such as the election of directors to Kenvue’s board, the filing said. J&J plans to distribute the remaining shares of common stock to its shareholders later this year. The company expected to price 151 million shares between $20 and $23 per share, according to a preliminary prospectus it filed with the Securities and Exchange Commission last week.

The spinoff, the biggest IPO since EV maker Rivian went public in November 2021, alone may not completely turn around the moribund IPO market, which plummeted in 2022. We’ve always believed in the power of new perspectives and insights to drive innovation. That’s why our iconic brands have helped generations take care of themselves and their loved ones for more than 135 years. Our work impacts consumers and colleagues, communities and generations, in daily rituals and in the moments that matter most.

Solutions for your daily needs

For the first quarter, which ended April 2, Kenvue estimates it raked in sales of $3.85 billion and net income of around $330 million. Annual sales growth through 2025 is projected to be about 3% to 4% globally, according to the filing. Kenvue is profitable and expects modest growth over the next few years, the company said in the filing. J&J will control 91.9% of Kenvue after the IPO — or 90.8% if underwriters exercise their options to purchase additional shares, according to the prospectus filing. Shares will begin trading Thursday on New York Stock Exchange under the ticker “KVUE.”

Kenvue’s chief people officer, chief corporate affairs officer, chief technology and data officer, chief scientific officer and group presidents for different regions around the world are also from J&J. “Johnson & Johnson will continue to control the direction of our business, and the concentrated ownership of our common stock may prevent you and other shareholders from influencing significant decisions,” Kenvue said in the filing. Until then, Kenvue will https://www.forexbox.info/used-car-dealer-in-kissimmee-tampa-orlando-miami/ qualify as a “controlled company” under the corporate governance rules of the NYSE, the filing said. That will allow Kenvue to avoid certain listing standards, including a requirement that the company’s board be composed of a majority of independent directors. Meanwhile, Kenvue is chock full of household names familiar to investors and the larger public, such as Tylenol, Band-Aid, Listerine, Aveeno, Neutrogena, and J&J’s namesake baby powder and shampoo.

Then we move fast to bring real solutions into communities, homes and hands. With leading science and knowledge, we educate and empower — so that when people need us, corporate bond yield curve papers and data 2020 they can rely on our brands. We’re driven to win for those we serve, and when we care fiercely for them and one another, we can deliver the best possible care.

J&J faces thousands of allegations that its talc baby powder and other talc products caused cancer. Some of those products fall under the company’s consumer health business. If you’ve heard of Kenvue, you may already know that we’re a global consumer health company. But beyond our portfolio of iconic brands, Kenvue is built on a foundation of core values, which fuel our 22,000+ global team members every day.

Kenvue’s debut also marks the largest restructuring in J&J’s 135-year history. J&J announced the split in late 2021 as a bid to streamline operations and refocus on its pharmaceutical and medical device divisions. With empathy, we unearth extraordinary breakthroughs in everyday care, and with courage and conviction, we bring them to life. We boldly pursue more innovative ways of working, pioneer solutions that improve lives, and create products that create categories — then improve them again and again. Our skin health & beauty brands bring together next-generation science and partnerships with skin experts to create high-performance products for healthy skin.

You should view the Media section in order to receive the most current information made available by Kenvue. Thibaut Mongon, J&J’s executive vice president and worldwide chair of consumer health, will serve as CEO of the newly public company. Johnson & Johnson’s consumer health business Kenvue priced its IPO at $22 per share Wednesday, toward the high end of its stated range, in an upsized deal that would bring in about $3.8 billion. Formerly the Consumer Healthcare division of Johnson & Johnson,[2] Kenvue is the proprietor of well-known brands such as Aveeno,[3] Band-Aid,[4] Benadryl, Zyrtec,[5] Johnson’s,[6] Listerine,[7] Mylanta, Neutrogena,[3] Tylenol,[7] and Visine. And products in the essential health division, including baby products, mouthwash and dental rinses, sanitary protection and wound care, saw $4.6 billion in net sales, representing 31% of all-in revenue.

Empowered healthcare starts with you

Together, we create an inclusive place where we can bring our whole selves. Our committed collaboration fuels our relentless external competitive drive — because the stronger our bonds are, the stronger our brands are, too. Our essential health brands have been raising standards of personal care across baby care, wound care, oral care and sanitary protection for generations.

Your use of the information on this site is subject to our Terms of Service in the Legal Notice. You should view the Media section in order to receive the most current information made available by Kenvue. Paul Ruh, J&J’s chief financial officer of consumer health and a former PepsiCo executive, will serve as CFO, https://www.forex-world.net/software-development/aws-cloud-engineer-job-description-guide-sample/ and Meredith Stevens, J&J’s worldwide vice president of the company’s consumer health supply chain department, will serve as COO. Use of this site constitutes your consent to application of such laws and regulations. Your use of the information on this site is subject to our Terms of Service in the Legal Notice.

In May 2023, Kenvue made our debut as a public company on the New York Stock Exchange, trading under the KVUE ticker symbol. Today, Kenvue is the world’s largest pure-play consumer health company by revenue, with annual sales of ~$15 billion in 2022. This site is governed solely by applicable U.S. laws and governmental regulations. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy.

Kenvue affirms commitment to its Healthy Lives Mission

Among those products are shampoos, conditioners, hair loss treatments and skin care. The company’s self-care unit, which includes products for eye care, cough and cold, and vitamins, generated $6 billion in net sales for 2022, accounting for 40% of total revenue. Each of the three divisions was profitable on an adjusted operating income basis, the company said in the filing. Overall, Kenvue said 2022 sales were “well balanced” across the company’s three business divisions.

We are committed to continuously improving our sustainability efforts through our brands, packaging and operations, delivering on the expectations of today’s consumers. Our Healthy Lives Mission strives to advance the well-being of both your health and the planet’s health. We’re working to improve the sustainability of our products, packaging and operations to build lasting positive change for people, communities and the one planet we call home. For example, the creation of BAND-AID® Brand HYDRO SEAL™ acne blemish patches was born out of viral social media skincare trends. The development of this product demonstrates how Kenvue boldly pursues innovative ways to work, creating solutions that can genuinely improve people’s lives. From best practices to best-in-class products, we learn, test, partner and optimize.